Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem

Most people treat biology as a bespoke, messy science. Josh Meier and Matt McPartlon, co-founders of Chai Discovery, treat it as an engineering problem. They make the case that drug design obeys the bitter lesson: scale data, models, and compute, and the model can learn what a hand-built pipeline simply couldn't capture. The results are concrete: Chai-2 pushed de novo antibody design from a sub 0.1% hit rate to 16%, turning a needle-in-a-haystack search into something more like designing a key to fit a lock. Josh argues, counterintuitively, that biology is more verifiable than code, and explains why the goal should be more lab experiments, not fewer. Their bet: a design suite that collapses drug discovery from nine months to nine days, and arms the pharma industry rather than competing with it.